Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease

Endocrinology

Volumn 139, Issue 8, 1998, Pages 3613-3619

  Carlomagno, Francesca ^a   Melillo, Rosa Marina ^a   Visconti, Roberta ^a   Salvatore, Giuliana ^a   De Vita, Gabriella ^a   Lupoli, Gelsy ^a   Yu, Yanbin ^b   Jing, Shuqian ^b   Vecchio, Giancarlo ^a,e   Fusco, Alfredo ^c   Santoro, Massimo ^a,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b AMGEN INC   (United States)

^c UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

^d Ctro Endocrinol ed Oncol S   (Italy)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; ONCOPROTEIN; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE MUTATION; GENE REARRANGEMENT; HIRSCHSPRUNG DISEASE; MITOGENESIS; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 7844232410     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.8.6124     Document Type: Article

References (43)

1. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H 1988 Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3:571-578
2. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563
3. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460
4. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA 1993 Mutations in the RET protooncogene are associated with MEN2A and FMTC. Hum Mol Genet 2:851-856
5. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow P, Donis-Keller H 1994 Single missense mutation in the tyrosine-kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579-1583
6. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JWM, van Amstel HCP, Romeo G, Lips CJM, Buys CHCM 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376
7. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson C, Tunnacliffe A, Ponder BAJ 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet 3:237-241
8. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, LaCroix A, Frilling A, Ponder BAJ, Mulligan LM, 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579
9. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP 1995 Germ-line mutations of MEN2A and MEN2B activate RET as a dominant transforming gene by different molecular mechanisms. Science 267:381-383
10. Asai N, Iwashita T, Matsuyama M, Takahashi M 1995 Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15:1613-1619
11. Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M 1997 The different ret activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57:391-395
12. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M 1997 Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 57:2870-2872
13. Deleted in proof
14. Songyang Z, Carraway III KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer BJ, Cantley LC 1995 Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373:536-540
15. Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Bocciardi R, Lerone M, Kaarlainen H, Martucciello G 1994 Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 367:377-378
16. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fékété C, Ponder BAJ, Munnich A 1994 Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367:378-380
17. Pasini B, Borrello MG, Greco A, Bongarzone I, Luo Y, Mondellini P, Alberti L, Miranda C, Arighi E, Bocciardi R, Seri M, Barone V, Radice MT, Romeo G, Pierotti M 1995 Loss of function effect of RET mutations causing Hirschsprung's disease. Nat Genet 10:35-40
18. Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M 1996 Molecular heterogeneity of RET loss of function in Hirschsprung's disease. EMBO J 15:2717-2725
19. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM 1996 GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85:1113-1124
20. Treanor JJS, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A 1996 Characterization of a multicomponent receptor for GDNF. Nature 382:80-83
21. Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sleber BA, Grigoriu M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumae U, Sariola H, Saarma M, Ibánez CF 1996 Functional receptor for GDNF encoded by the c-Ret proto-oncogene. Nature 381:785-789
22. Durbec P, Marcos-Gutierrez CV, Kilkenny C, Grigoriu M, Wartiowaara K, Suvanto P, Smith D, Ponder B, Costantini F, Saarma M, Sariola H, Pachnis V 1996 GDNF signalling through the Ret receptor tyrosine kinase. Nature 381:789-793
23. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V 1994 Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367:380-383
24. Sanchez M, Silos-Santiago I, Frisen J, He B, Lira SA, Barbacid M 1996 Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382:70-73
25. Klein RD, Sherman D, Ho WH, Stone D, Bennett GL, Moffat B, Vandlen R, Simmons L, Gu Q, Hongo JA, Devaux B, Poulsen K, Armanini M, Nozaki C, Asai N, Goddard A, Phillips H, Hendereon CE, Takahashi M, Rosenthal A 1997 A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 387:717-721
26. Buj-Bello A, Adu J, Pinon LG, Horton A, Thompson J, Rosenthal A, Chinchetru M, Buchman VL, Davies AM 1997 Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase. Nature 387:721-724
27. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Schlessinger J, Aaronson SA 1987 ErbB-2 is a potent oncogene when overexpressed in NIH-3T3 cells. Science 237:178-181
28. Chomczynski P, Sacchi N 1987 A single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
29. Sabath DE, Broome HE, Prystowsky MB 1990 Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene 91:185-191
30. Santoro M, Wong TW, Aroca P, Santos E, Matoskova B, Grieco M, Fusco A, Di Fiore PP 1994 An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway. Mol Cell Biol 14:663-675
31. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti M, Pelicci PG, Pierotti MA 1994 The oncogenic versions of the Ret and Trk tyrosine kinases bind She and Grb2 adaptor proteins. Oncogene 9:1661-1668
32. van Weering DH, Medema JP, van Puijenbroek A, Burgering BM, Baas PD, Bos JL 1995 Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. Oncogene 11:2207-2214
33. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Borrello MG, Segatto O, Di Fiore PP, Pelicci PG 1995 Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 11:899-907
34. Arighi E, Alberti L, Torriti F, Ghizzoni S, Rizzetti MG, Pelicci G, Pasini B, Bongarzone I, Piutti C, Pierotti MA, Borrello MG 1997 Identification of Shc docking site on Ret tyrosine kinase. Oncogene 14:773-782
35. Lorenzo MJ, Gish GD, Houghton C, Stonehouse TJ, Pawson T, Ponder BA, Smith DP 1997 RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. Oncogene 14:763-771
36. Asai N, Murakami H, Iwashita T, Takahashi M 1996 A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with she adaptor proteins. J Biol Chem 271:17644-17649
37. Smith DP, Eng C, Ponder BAJ 1994 Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. J Cell Sci 18:43-49
38. Moley JF1997 The molecular genetics of multiple endocrine neoplasia type 2A and related syndromes. Annu Rev Med 48:409-420
39. Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M 1997 Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 15:393-402
40. Smith DP, Houghton C, Ponder BA 1997 Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213-1217
41. Rodrigues GA, Park M 1994 Oncogenic activation of tyrosine kinases. Curr Opin Genet Dev 4:15-24
42. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bermues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hugson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B 1997 Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73
43. Mak YF, Ponder BA 1996 RET oncogene. Curr Opin Genet Dev 6:82-86